European generics firms, squeezed between innovators and payers, seek diversity
This article was originally published in SRA
Executive Summary
Mixed sentiments about the future of the European generic medicines sector were in evidence at the annual meeting of the European Generic medicines Association in Lisbon on 16-17 June1. Upbeat forecasts from industry figures contrasted with a more downbeat assessment from some consultancy firms in the face of the innovation slowdown, competition from R&D firms and the challenges posed by the biosimilars market.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.